Robbins Arroyo LLP is Investigating the Officers and Directors of Celgene Corporation (CELG) on Behalf of Shareholders

San Diego, California, UNITED STATES


SAN DIEGO and SUMMIT, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Celgene Corporation breached their fiduciary duties to shareholders. Celgene discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases.

View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/celgene-corporation

Celgene Is Being Investigated for Marketing Cancer Therapies for Unapproved Uses

Since 2011, Celgene has been investigated by several United States Attorneys' Offices, including the Central District of California, Northern District of Alabama, and the Eastern District of Texas, for aggressively marketing THALOMID and REVLIMID for unapproved uses. The investigations also include possible improper payments to physicians for prescribing the company's top selling cancer drugs, as well as concerns that the company failed to fully disclose possible side effects and necessary warnings about using THALOMID and REVLIMID.

Celgene Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.



        

Contact Data